- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT05638295
Testování použití AMG 510 (sotorasib) a panitumumabu jako cílené léčby pro KRAS G12C mutantní solidní nádory (A ComboMATCH Treatment Trial)
Randomizovaná studie fáze II AMG 510 (sotorasib) s nebo bez panitumumabu u pokročilých solidních nádorů: ComboMATCH léčba
This phase II ComboMATCH treatment trial tests how well AMG 510 (sotorasib) with or without panitumumab works in treating patients with KRAS G12C mutant solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Sotorasib is in a class of medications called KRAS inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop or slow the spread of cancer cells. Panitumumab is in a class of medications called monoclonal antibodies. It works by slowing or stopping the growth of cancer cells. Giving combination panitumumab and sotorasib may kill more tumor cells in patients with advanced solid tumors with KRAS G12C mutation.
Přehled studie
Postavení
Detailní popis
PRIMARY OBJECTIVES:
I. To evaluate the efficacy of the combination of AMG 510 (sotorasib) and panitumumab as compared to AMG 510 (sotorasib) alone in patients with advanced/metastatic KRAS G12C mutated solid tumors (except colorectal carcinoma [CRC] and non-small cell lung carcinoma [NSCLC]) as measured by progression free survival (Cohort 1).
II. To evaluate the efficacy of the combination of AMG 510 (sotorasib) and panitumumab in patients with advanced/metastatic KRAS G12C mutated solid tumors that have progressed on a prior KRAS G12C inhibitor as measured by response rate (Cohort 2).
SECONDARY OBJECTIVES:
I. To evaluate the efficacy of the combination of AMG 510 (sotorasib) and panitumumab as compared to AMG 510 alone in patients with advanced/metastatic KRAS G12C mutated solid tumors (except CRC and NSCLC) as measured by response rate, disease control rate, and overall survival (Cohort 1).
II, To evaluate the efficacy of the combination of AMG 510 (sotorasib) and panitumumab in patients with advanced/metastatic KRAS G12C mutated solid tumors that have progressed on a prior KRAS G12C inhibitor as measured by disease control rate, progression free survival (PFS), and overall survival (Cohort 2).
III. To further evaluate the safety and tolerability of the combination of AMG 510 (sotorasib) and panitumumab.
IV. To collect tissue and provide it to the ComboMATCH Registration Protocol to assess concordance between the diagnostic tumor mutation profile generated by the Designated Laboratories, the pre-treatment biopsy mutation profile, and the pre-treatment circulating tumor-derived deoxyribonucleic acid (DNA) (ctDNA) mutation profile from plasma, as described in ComboMATCH Registration Protocol.
CORRELATIVE EXPLORATORY OBJECTIVES:
I. To investigate the impact of concomitant mutations on the clinical benefit. II. To evaluate if changes in circulating tumor DNA (ctDNA) over time correlate with response to treatment.
III. To evaluate the relative mutant allele fraction of KRAS mutation as a predictor of clinical benefit.
IV. To evaluate if ERK 1/2 and PI3K pathway activation correlate with response and/or resistance.
OUTLINE: Patients are assigned to 1 of 2 cohorts.
COHORT I: Patients who have never received a KRAS G12C inhibitor are randomized to arms A or B.
ARM A: Patients receive sotorasib orally (PO) once daily (QD) on days 1-28 and panitumumab intravenously (IV) on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples, biopsy, and computed tomography (CT) or magnetic resonance imaging (MRI) on study.
ARM B: Patients receive sotorasib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross-over to cohort II. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study.
COHORT II: Patients who have received a KRAS G12C inhibitor are assigned to arm C.
ARM C: Patients receive combination therapy as in Arm A.
After completion of study treatment, patients are followed up at 30 days and then every 3-6 months for up to 36 months.
Typ studie
Zápis (Odhadovaný)
Fáze
- Fáze 2
Kontakty a umístění
Studijní místa
-
-
Alabama
-
Birmingham, Alabama, Spojené státy, 35233
- University of Alabama at Birmingham Cancer Center
-
Mobile, Alabama, Spojené státy, 36688
- University of South Alabama Mitchell Cancer Institute
-
-
California
-
Los Angeles, California, Spojené státy, 90048
- Cedars-Sinai Medical Center
-
Los Angeles, California, Spojené státy, 90025
- The Angeles Clinic and Research Institute - West Los Angeles Office
-
Palo Alto, California, Spojené státy, 94304
- VA Palo Alto Health Care System
-
-
Florida
-
Aventura, Florida, Spojené státy, 33180
- UM Sylvester Comprehensive Cancer Center at Aventura
-
Coral Gables, Florida, Spojené státy, 33146
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Coral Springs, Florida, Spojené státy, 33065
- UM Sylvester Comprehensive Cancer Center at Coral Springs
-
Deerfield Beach, Florida, Spojené státy, 33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Hollywood, Florida, Spojené státy, 33021
- UM Sylvester Comprehensive Cancer Center at Hollywood
-
Jacksonville, Florida, Spojené státy, 32224-9980
- Mayo Clinic in Florida
-
Miami, Florida, Spojené státy, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami, Florida, Spojené státy, 33176
- UM Sylvester Comprehensive Cancer Center at Kendall
-
Plantation, Florida, Spojené státy, 33324
- UM Sylvester Comprehensive Cancer Center at Plantation
-
-
Idaho
-
Boise, Idaho, Spojené státy, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Boise, Idaho, Spojené státy, 83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell, Idaho, Spojené státy, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Coeur d'Alene, Idaho, Spojené státy, 83814
- Kootenai Health - Coeur d'Alene
-
Fruitland, Idaho, Spojené státy, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Spojené státy, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Spojené státy, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa, Idaho, Spojené státy, 83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls, Idaho, Spojené státy, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, Spojené státy, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
-
Illinois
-
Barrington, Illinois, Spojené státy, 60010
- Advocate Good Shepherd Hospital
-
Chicago, Illinois, Spojené státy, 60612
- University of Illinois
-
Chicago, Illinois, Spojené státy, 60612
- John H Stroger Jr Hospital of Cook County
-
Chicago, Illinois, Spojené státy, 60657
- Advocate Illinois Masonic Medical Center
-
Crystal Lake, Illinois, Spojené státy, 60014
- AMG Crystal Lake - Oncology
-
Danville, Illinois, Spojené státy, 61832
- Carle at The Riverfront
-
Decatur, Illinois, Spojené státy, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Spojené státy, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Downers Grove, Illinois, Spojené státy, 60515
- Advocate Good Samaritan Hospital
-
Effingham, Illinois, Spojené státy, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Spojené státy, 62401
- Carle Physician Group-Effingham
-
Elgin, Illinois, Spojené státy, 60123
- Advocate Sherman Hospital
-
Hazel Crest, Illinois, Spojené státy, 60429
- Advocate South Suburban Hospital
-
Libertyville, Illinois, Spojené státy, 60048
- Condell Memorial Hospital
-
Libertyville, Illinois, Spojené státy, 60048
- AMG Libertyville - Oncology
-
Mattoon, Illinois, Spojené státy, 61938
- Carle Physician Group-Mattoon/Charleston
-
Maywood, Illinois, Spojené státy, 60153
- Loyola University Medical Center
-
Normal, Illinois, Spojené státy, 61761
- Carle Cancer Institute Normal
-
Normal, Illinois, Spojené státy, 61761
- Carle BroMenn Medical Center
-
O'Fallon, Illinois, Spojené státy, 62269
- Cancer Care Center of O'Fallon
-
Oak Lawn, Illinois, Spojené státy, 60453-2699
- Advocate Christ Medical Center
-
Oak Lawn, Illinois, Spojené státy, 60453
- Advocate Outpatient Center - Oak Lawn
-
Palos Heights, Illinois, Spojené státy, 60463
- Advocate High Tech Medical Park
-
Park Ridge, Illinois, Spojené státy, 60068
- Advocate Lutheran General Hospital
-
Shiloh, Illinois, Spojené státy, 62269
- Memorial Hospital East
-
Springfield, Illinois, Spojené státy, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Spojené státy, 62702
- Springfield Clinic
-
Springfield, Illinois, Spojené státy, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, Spojené státy, 61801
- Carle Cancer Center
-
-
Iowa
-
Ankeny, Iowa, Spojené státy, 50023
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Des Moines, Iowa, Spojené státy, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Spojené státy, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Waukee, Iowa, Spojené státy, 50263
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
-
Kentucky
-
Lexington, Kentucky, Spojené státy, 40536
- University of Kentucky/Markey Cancer Center
-
-
Maine
-
Brewer, Maine, Spojené státy, 04412
- Lafayette Family Cancer Center-EMMC
-
-
Maryland
-
Baltimore, Maryland, Spojené státy, 21201
- University of Maryland/Greenebaum Cancer Center
-
Bethesda, Maryland, Spojené státy, 20892
- National Institutes of Health Clinical Center
-
Bethesda, Maryland, Spojené státy, 20889-5600
- Walter Reed National Military Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, Spojené státy, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brighton, Michigan, Spojené státy, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton, Michigan, Spojené státy, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, Spojené státy, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton, Michigan, Spojené státy, 48188
- Trinity Health Medical Center - Canton
-
Chelsea, Michigan, Spojené státy, 48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea, Michigan, Spojené státy, 48118
- Chelsea Hospital
-
Dearborn, Michigan, Spojené státy, 48124
- Corewell Health Dearborn Hospital
-
Farmington Hills, Michigan, Spojené státy, 48336
- Corewell Health Farmington Hills Hospital
-
Flint, Michigan, Spojené státy, 48503
- Hurley Medical Center
-
Flint, Michigan, Spojené státy, 48503
- Genesee Hematology Oncology PC
-
Flint, Michigan, Spojené státy, 48503
- Genesys Hurley Cancer Institute
-
Flint, Michigan, Spojené státy, 48503
- Cancer Hematology Centers - Flint
-
Lansing, Michigan, Spojené státy, 48912
- University of Michigan Health - Sparrow Lansing
-
Livonia, Michigan, Spojené státy, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Pontiac, Michigan, Spojené státy, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Royal Oak, Michigan, Spojené státy, 48073
- Corewell Health William Beaumont University Hospital
-
Royal Oak, Michigan, Spojené státy, 48073
- Corewell Health Children's
-
Saginaw, Michigan, Spojené státy, 48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Spojené státy, 48601
- MyMichigan Medical Center Saginaw
-
Tawas City, Michigan, Spojené státy, 48764
- MyMichigan Medical Center Tawas
-
Troy, Michigan, Spojené státy, 48085
- Corewell Health Beaumont Troy Hospital
-
West Branch, Michigan, Spojené státy, 48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Ypsilanti, Michigan, Spojené státy, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Ypsilanti, Michigan, Spojené státy, 48106
- Huron Gastroenterology PC
-
-
Minnesota
-
Deer River, Minnesota, Spojené státy, 56636
- Essentia Health - Deer River Clinic
-
Duluth, Minnesota, Spojené státy, 55805
- Essentia Health Cancer Center
-
Hibbing, Minnesota, Spojené státy, 55746
- Essentia Health Hibbing Clinic
-
Rochester, Minnesota, Spojené státy, 55905
- Mayo Clinic in Rochester
-
Sandstone, Minnesota, Spojené státy, 55072
- Essentia Health Sandstone
-
Virginia, Minnesota, Spojené státy, 55792
- Essentia Health Virginia Clinic
-
-
Missouri
-
Cape Girardeau, Missouri, Spojené státy, 63703
- Saint Francis Medical Center
-
City of Saint Peters, Missouri, Spojené státy, 63376
- Siteman Cancer Center at Saint Peters Hospital
-
Creve Coeur, Missouri, Spojené státy, 63141
- Siteman Cancer Center at West County Hospital
-
St Louis, Missouri, Spojené státy, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Spojené státy, 63129
- Siteman Cancer Center-South County
-
St Louis, Missouri, Spojené státy, 63136
- Siteman Cancer Center at Christian Hospital
-
-
Montana
-
Anaconda, Montana, Spojené státy, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Spojené státy, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, Spojené státy, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, Spojené státy, 59405
- Benefis Sletten Cancer Institute
-
Kalispell, Montana, Spojené státy, 59901
- Logan Health Medical Center
-
Missoula, Montana, Spojené státy, 59804
- Community Medical Center
-
-
Nevada
-
Las Vegas, Nevada, Spojené státy, 89102
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, Spojené státy, 89135
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Las Vegas, Nevada, Spojené státy, 89183
- OptumCare Cancer Care at Fort Apache
-
-
New Jersey
-
New Brunswick, New Jersey, Spojené státy, 08903
- Rutgers Cancer Institute of New Jersey
-
-
New Mexico
-
Albuquerque, New Mexico, Spojené státy, 87106
- University of New Mexico Cancer Center
-
-
New York
-
Buffalo, New York, Spojené státy, 14263
- Roswell Park Cancer Institute
-
Mineola, New York, Spojené státy, 11501
- NYU Langone Hospital - Long Island
-
New York, New York, Spojené státy, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
-
Ohio
-
Columbus, Ohio, Spojené státy, 43214
- Riverside Methodist Hospital
-
Columbus, Ohio, Spojené státy, 43214
- Columbus Oncology and Hematology Associates Inc
-
Columbus, Ohio, Spojené státy, 43228
- Doctors Hospital
-
Columbus, Ohio, Spojené státy, 43215
- Grant Medical Center
-
Dayton, Ohio, Spojené státy, 45415
- Dayton Physician LLC - Englewood
-
Delaware, Ohio, Spojené státy, 43015
- Delaware Health Center-Grady Cancer Center
-
Delaware, Ohio, Spojené státy, 43015
- Grady Memorial Hospital
-
Dublin, Ohio, Spojené státy, 43016
- Dublin Methodist Hospital
-
Dublin, Ohio, Spojené státy, 43016
- Columbus Oncology and Hematology Associates
-
Kettering, Ohio, Spojené státy, 45429
- Kettering Medical Center
-
Mansfield, Ohio, Spojené státy, 44903
- OhioHealth Mansfield Hospital
-
Marion, Ohio, Spojené státy, 43302
- OhioHealth Marion General Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Spojené státy, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Ontario, Oregon, Spojené státy, 97914
- Saint Alphonsus Cancer Care Center-Ontario
-
Portland, Oregon, Spojené státy, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Spojené státy, 97225
- Providence Saint Vincent Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Spojené státy, 19107
- Thomas Jefferson University Hospital
-
Willow Grove, Pennsylvania, Spojené státy, 19090
- Asplundh Cancer Pavilion
-
-
South Carolina
-
Boiling Springs, South Carolina, Spojené státy, 29316
- Prisma Health Cancer Institute - Spartanburg
-
Easley, South Carolina, Spojené státy, 29640
- Prisma Health Cancer Institute - Easley
-
Greenville, South Carolina, Spojené státy, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, Spojené státy, 29615
- Prisma Health Cancer Institute - Eastside
-
Greenville, South Carolina, Spojené státy, 29605
- Prisma Health Cancer Institute - Butternut
-
Greer, South Carolina, Spojené státy, 29650
- Prisma Health Cancer Institute - Greer
-
Seneca, South Carolina, Spojené státy, 29672
- Prisma Health Cancer Institute - Seneca
-
-
South Dakota
-
Rapid City, South Dakota, Spojené státy, 57701
- Rapid City Regional Hospital
-
-
Tennessee
-
Bristol, Tennessee, Spojené státy, 37620
- Bristol Regional Medical Center
-
Johnson City, Tennessee, Spojené státy, 37604
- Regional Cancer Center at Johnson City Medical Center
-
Kingsport, Tennessee, Spojené státy, 37660
- Ballad Health Cancer Care - Kingsport
-
Kingsport, Tennessee, Spojené státy, 37660
- Wellmont Holston Valley Hospital and Medical Center
-
Nashville, Tennessee, Spojené státy, 37232
- Vanderbilt University/Ingram Cancer Center
-
-
Texas
-
Temple, Texas, Spojené státy, 76508
- Scott and White Memorial Hospital
-
-
Virginia
-
Bristol, Virginia, Spojené státy, 24201
- Ballad Health Cancer Care - Bristol
-
Charlottesville, Virginia, Spojené státy, 22908
- University of Virginia Cancer Center
-
Richmond, Virginia, Spojené státy, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Spojené státy, 23298
- VCU Massey Comprehensive Cancer Center
-
-
Washington
-
Seattle, Washington, Spojené státy, 98122
- Swedish Medical Center-First Hill
-
-
West Virginia
-
Charleston, West Virginia, Spojené státy, 25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
-
Wisconsin
-
Appleton, Wisconsin, Spojené státy, 54911
- ThedaCare Regional Cancer Center
-
Ashland, Wisconsin, Spojené státy, 54806
- Duluth Clinic Ashland
-
Berlin, Wisconsin, Spojené státy, 54923
- ThedaCare Cancer Care - Berlin
-
Burlington, Wisconsin, Spojené státy, 53105
- Aurora Cancer Care-Southern Lakes VLCC
-
Cudahy, Wisconsin, Spojené státy, 53110
- Aurora Saint Luke's South Shore
-
Germantown, Wisconsin, Spojené státy, 53022
- Aurora Health Care Germantown Health Center
-
Grafton, Wisconsin, Spojené státy, 53024
- Aurora Cancer Care-Grafton
-
Green Bay, Wisconsin, Spojené státy, 54311
- Aurora BayCare Medical Center
-
Janesville, Wisconsin, Spojené státy, 53548
- Mercyhealth Hospital and Cancer Center - Janesville
-
Kenosha, Wisconsin, Spojené státy, 53142
- Aurora Cancer Care-Kenosha South
-
La Crosse, Wisconsin, Spojené státy, 54601
- Gundersen Lutheran Medical Center
-
Madison, Wisconsin, Spojené státy, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Madison, Wisconsin, Spojené státy, 53718
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
-
Marinette, Wisconsin, Spojené státy, 54143
- Aurora Bay Area Medical Group-Marinette
-
Milwaukee, Wisconsin, Spojené státy, 53209
- Aurora Cancer Care-Milwaukee
-
Milwaukee, Wisconsin, Spojené státy, 53215
- Aurora Saint Luke's Medical Center
-
Milwaukee, Wisconsin, Spojené státy, 53233
- Aurora Sinai Medical Center
-
Neenah, Wisconsin, Spojené státy, 54956
- ThedaCare Regional Medical Center - Neenah
-
New London, Wisconsin, Spojené státy, 54961
- ThedaCare Cancer Care - New London
-
Oshkosh, Wisconsin, Spojené státy, 54904
- Vince Lombardi Cancer Clinic - Oshkosh
-
Oshkosh, Wisconsin, Spojené státy, 54904
- ThedaCare Cancer Care - Oshkosh
-
Racine, Wisconsin, Spojené státy, 53406
- Aurora Cancer Care-Racine
-
Shawano, Wisconsin, Spojené státy, 54166
- ThedaCare Cancer Care - Shawano
-
Sheboygan, Wisconsin, Spojené státy, 53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
Summit, Wisconsin, Spojené státy, 53066
- Aurora Medical Center in Summit
-
Two Rivers, Wisconsin, Spojené státy, 54241
- Vince Lombardi Cancer Clinic-Two Rivers
-
Waupaca, Wisconsin, Spojené státy, 54981
- ThedaCare Cancer Care - Waupaca
-
Wauwatosa, Wisconsin, Spojené státy, 53226
- Aurora Cancer Care-Milwaukee West
-
West Allis, Wisconsin, Spojené státy, 53227
- Aurora West Allis Medical Center
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
-
Patient must have enrolled onto EAY191 and must have been given a treatment assignment to ComboMATCH to EAY191-E5 based on the presence of an actionable mutation as defined in EAY191
-
Patient must be enrolled on the ComboMATCH Registration Protocol (EAY191) at the time of registration/randomization to the EAY191-E5 study
-
Patient must be >= 18 years of age
-
Patient must have a KRAS G12C alteration as determined by the ComboMATCH screening assessment
-
Patient must have disease that can be safely biopsied and agree to a pre-treatment biopsy or have tissue available from within 12 months prior to the date of registration on the ComboMATCH Registration Trial (EAY191-E5)
- NOTE: The current actionable marker of interest (aMOI)/actionable alteration list for this treatment trial can be found on the Cancer Trials Support Unit (CTSU) website: www.ctsu.org (final URL pending)
- NOTE: Novel/Dynamic aMOI can be submitted for review per the process described in the ComboMATCH registration protocol
-
Patient must have cytologically/histologically confirmed advanced/metastatic solid tumor
-
Patient must have progressed on at least one line of standard of care therapy in the advanced/metastatic setting
- NOTE: Patients who have progressed on a prior human epidermal growth factor receptor (EGFR) inhibitor will meet this criterion
-
Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 2 (or Karnofsky performance status >= 60%)
-
Patient must have at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) documented by imaging obtained within 28 days prior to registration/randomization
-
Patient must not have any serious active infection within 4 weeks prior to EAY191-E5 registration/randomization (e.g., requiring hospitalization and/or intravenous [IV] antibiotics) or currently receiving oral or IV antibiotics for the treatment of infection. Patients receiving prophylactic antibiotics are eligible
-
Patient must have the ability to retain oral medication and not have any clinically significant gastrointestinal abnormalities that might alter absorption
-
Patient must not have any history of or current evidence of non-infectious interstitial lung disease (ILD)/pneumonitis
-
Patient must not have a history of allergic reactions attributed to either of the study agents or to agents of similar chemical or biologic composition
-
Patient must have completed full treatment cycle 21 days prior to EAY191-E5 registration/randomization if they have received prior chemotherapy, biological cancer therapy, radiation therapy or an investigational agent/device. Patients must have recovered to Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or better from any adverse events due to prior cancer therapy (with the exception of alopecia)
-
Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to registration/randomization to rule out pregnancy. A patient of childbearing potential is defined as anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
-
Patient must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study and for at least 6 months after the last dose of protocol treatment. Patients must not breastfeed while receiving protocol treatment and for one week (7 days) after the last dose of AMG 510 (sotorasib) and 2 months after the last dose of panitumumab
-
Patients must not have neuropathy ≥ grade 2 within 14 days prior to registration/randomization
-
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression
-
Human immunodeficiency virus (HIV)-infected patients no effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
-
Patients with known history or current symptoms of cardiac history, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trail, patients should be class 2B or better
-
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (obtained ≤ 28 days prior to protocol registration/randomization)
-
Aspartate aminotransferase (AST) (serum (glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase ([SGPT]) < 3 x institutional upper limit of normal (obtained ≤ 28 days prior to protocol registration/randomization)
-
Creatinine =< 1.5 x institutional ULN OR creatinine clearance > 50 mL/min/1.73 m^2 for patients with creatinine levels > 1.5 mg/dL as per Cockcroft-Gault (obtained ≤ 28 days prior to protocol registration/randomization)
-
COHORT I: Patient must not have colorectal cancer or non-small cell lung cancer
-
COHORT I: Patient must not have been previously treated with a KRAS G12C inhibitor
-
COHORT II: Patient must have progressed after treatment at the recommended phase II dose (RP2D) of any KRAS G12C inhibitor
- NOTE: Patients on cohort 1 who experience progression on Regimen 2 (AMG 510 [sotorasib] alone) may be eligible to enroll on cohort 2 and receive combination treatment with panitumumab and AMG 510 (sotorasib). Patients must meet performance status requirements and laboratory values as above and must be begin treatment within 7 days of enrollment. Migration to cohort 2 must take place within 6 months of progression, with no intervening anti-cancer therapy given.
- NOTE: Cohort migration following disease progression is dependent on a slot being available. MATCHBox makes the new treatment assignment following initiation of a step 2 registration for this treatment trial
-
COHORT II: Patient must not have been previously treated with a KRAS G12C inhibitor in combination with an EGFR inhibitor
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Cohort I Arm A (sotorasib, panitumumab)
Patients receive sotorasib PO QD on days 1-28 and panitumumab IV on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study. |
Undergo MRI
Ostatní jména:
Undergo collection of blood
Ostatní jména:
Undergo CT scan
Ostatní jména:
Undergo tumor biopsy
Ostatní jména:
Given IV
Ostatní jména:
Given PO
Ostatní jména:
|
|
Aktivní komparátor: Cohort I Arm B (sotorasib)
Patients receive sotorasib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross-over to cohort II. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study. |
Undergo MRI
Ostatní jména:
Undergo collection of blood
Ostatní jména:
Undergo CT scan
Ostatní jména:
Undergo tumor biopsy
Ostatní jména:
Given PO
Ostatní jména:
|
|
Experimentální: Cohort II (sotorasib, panitumumab)
Patients receive combination therapy as in Arm A. |
Undergo MRI
Ostatní jména:
Undergo collection of blood
Ostatní jména:
Undergo CT scan
Ostatní jména:
Undergo tumor biopsy
Ostatní jména:
Given IV
Ostatní jména:
Given PO
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Progression-free survival (PFS) (Cohort I)
Časové okno: From registration to documented disease progression or death from any cause, assessed up to 3 years
|
PFS will be compared between the arms using a one-sided log rank test with 10% type I error. Cox's proportional hazards model will be used to estimate the PFS hazard ratio between the treatment arms and a two-sided 80% confidence interval will be reported (to correspond to the one-sided 10% type I error). Confidence intervals on most other quantities will use the two-sided 90% level. |
From registration to documented disease progression or death from any cause, assessed up to 3 years
|
|
Best objective response (Cohort II)
Časové okno: From the start of the treatment until disease progression/recurrence, assessed up to 3 years
|
Will be evaluated using the criteria defined by Response Evaluation Criteria in Solid Tumors) version 1.1 for patients with solid tumors. |
From the start of the treatment until disease progression/recurrence, assessed up to 3 years
|
|
Overall response rate (ORR) (Cohort II)
Časové okno: From the time measurement criteria are met for complete response or partial response (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, assessed up to 3 years
|
The exact 90% confidence interval on the ORR (determined using the method of Atkinson and Brown) will be reported. If the number of analyzable cases is less than 35, a 5% one-sided test will still be used. |
From the time measurement criteria are met for complete response or partial response (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, assessed up to 3 years
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Overall survival (OS) (Cohort I)
Časové okno: Up to 3 years
|
OS distributions by treatment will be estimated and 90% confidence intervals on estimated rates at 6 and 12 months will be reported. The OS hazard ratio will be estimated using Cox proportional hazards model and a 90% confidence interval reported. |
Up to 3 years
|
|
ORR (Cohort I)
Časové okno: Up to 3 years
|
Will be compared using Fisher's exact test and exact 90% confidence intervals for the rates in each arm will be computed. |
Up to 3 years
|
|
Disease control rates (Cohort I)
Časové okno: From the start of the treatment until the criteria for progression are met, assessed up to 3 years
|
Will be compared using Fisher's exact test and exact 90% confidence intervals for the rates in each arm will be computed. |
From the start of the treatment until the criteria for progression are met, assessed up to 3 years
|
|
PFS (Cohort II)
Časové okno: At 6 and 12 months, assessed up to 3 years
|
Will be estimated and 90% confidence intervals on estimated rates will be reported. |
At 6 and 12 months, assessed up to 3 years
|
|
OS (Cohort II)
Časové okno: At 6 and 12 months, assessed up to 3 years
|
Will be estimated and 90% confidence intervals on estimated rates will be reported. |
At 6 and 12 months, assessed up to 3 years
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Kristen R Spencer, ECOG-ACRIN Cancer Research Group
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Patologické procesy
- Novotvary
- Neoplastické procesy
- Patologické stavy, příznaky a symptomy
- Metastáza novotvaru
- Aminokyseliny, peptidy a proteiny
- Proteiny
- Vyšetřovací techniky
- Klinické laboratorní techniky
- Diagnostické techniky a postupy
- Diagnóza
- Chirurgické postupy, operativní
- Cytologické techniky
- Cytodiagnosis
- Protilátky, monoklonální, humanizované
- Protilátky, monoklonální
- Protilátky
- Imunoglobuliny
- Imunoproteiny
- Krevní proteiny
- Sérové globuliny
- Globuliny
- Diagnostické techniky, chirurgické
- Techniky chemie, analytické
- Analýza spektra
- Panitumumab
- Biopsie
- Manipulace se vzorkem
- Magnetická rezonanční spektroskopie
- Sotorasib
Další identifikační čísla studie
- NCI-2022-09876
- U10CA180820 (Grant/smlouva NIH USA)
- NCI-2022-09876 (Identifikátor registru: CTRP (Clinical Trial Reporting Program))
- EAY191-E5 (Jiný identifikátor: CTEP)
- EAY191-E5 (Jiný identifikátor: ECOG-ACRIN Cancer Research Group)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
produkt vyrobený a vyvážený z USA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .